Entries by William Allbrook

Cellesce Appoints Dr Mark Treherne as CEO

Cellesce has appointed Dr. Mark Treherne as its CEO. Mark, a veteran of the biotech industry, will lead the Company through the next phase of its development programme and commercialisation phase. Cellesce’s pioneering organoid expansion technology is focused on cancer research and compound library screening at scale for drug discovery. Mark obtained his PhD in […]

Cellesce Announces Fundraising to Grow its Cancer Organoid Business

Cellesce the cancer organoid bioprocessing and scale-up company has announced a successful six-figure funding round that will open up opportunities to introduce its organoid scale-up and expansion technology to the oncology drug discovery screening market. This funding round has, once again, been led by the Development Bank of Wales, a measure of the confidence it […]

Cancer organoids to model therapy response

Previously, we briefly commented on the interest generated by the significant study by Georgios Vlachogiannis and co-workers at the Institute of Cancer Research in London, “Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.” This post looks in a bit more detail at this paper which was published in Science on February 23rd, and which […]

‘Mini-tumours’ created to battle cancer

The Today programme on BBC Radio 4 featured a news piece on Friday 23rd February 2018 which is a timely follow on to our previous news piece ‘Organoids – Method of the Year.’ The piece reported by the James Gallagher, the BBC’s Health and Science correspondent, focused on recent research where scientists have been able to predict […]

Organoids – Method of the Year

In the last few years fundamental cell biology research has moved from studies in two dimensions (2D) looking at cells on flat plastic plates to more comprehensive tools and understanding of how cells work in three dimensions (3D) both singly and in connection to other cells. 3D cell aggregates can be random constructs, or as […]

Cellesce Moves to New Lab and Office in the Cardiff Medicentre

Cellesce, has moved to new state of the art lab space in the Cardiff Medicentre. This will be the base for continuing organoid research and scale-up operations. The Medicentre is ideally located in Central Cardiff and in close proximity to Cardiff University, a Cellesce partner. The Medicentre also provides sufficient space to accommodate Cellesce’s planned […]

,

Cellesce Launches Colorectal Tumour Organoids Using its Bioreactor Expansion Technology

Cellesce, has formally launched and published the supporting data package for its first range of colorectal organoids. Based on three and a half years of bioprocess development research Cellesce has now successfully grown, reliably expanded and characterised a range of 10 novel organoids. Ethically derived from colorectal cancer patients, these organoids open up exciting new […]